Quorum Innovations Overview
Latest Deal Type
Series A
(Cancelled)
Quorum Innovations General Information
Description
Developer of human microbiome therapeutics designed to treat diseases of tissue barrier deficiency. The company's microbiome therapeutic treatments engage the body's immune system to treat a broad range of pathogens in biofilm form, and the company's discovery platform allows the discovery effort to focus on high therapeutic yield and target organ-relevant, safe and scalable therapeutics, enabling physicians to better solve the problem of antibiotic resistance.
Want to dig into this profile?
We’ll help you find what you need
Learn more
Quorum Innovations Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 3. Early Stage VC (Series A) |
|
|
|
|
Cancelled |
Startup |
| 2. Early Stage VC |
|
|
|
|
Completed |
Startup |
| 1. Debt - General |
06-Feb-2014 |
|
|
|
Completed |
Generating Revenue |
Quorum Innovations Executive Team (6)
| Name |
Title |
Board Seat |
Contact Info |
| Dirk Henson |
Chief Executive Officer |
|
|
| Eva Berkes MD |
Co-Founder, Chief Scientific Officer & Board Member |
|
|
| Nicholas Monsul MD |
Chairman & Co-Founder |
|
|
| Fredrick Boehm JD |
Vice President, Patent & Legal Affairs & Board Member |
|
|
2 Former Executives
Quorum Innovations Board Members (3)
| Name |
Representing |
Role |
Since |
| Eva Berkes MD |
Quorum Innovations |
Co-Founder, Chief Scientific Officer & Board Member |
000 0000
|
| Fredrick Boehm JD |
Quorum Innovations |
Vice President, Patent & Legal Affairs & Board Member |
000 0000
|
| Nicholas Monsul MD |
Quorum Innovations |
Chairman & Co-Founder |
000 0000
|